Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome

Annals of the Rheumatic Diseases

Volumn 70, Issue 9, 2011, Pages 1652-1654

  Vargas Hitos, José Antonio ^a   Ateka Barrutia, Oier ^b   Sangle, Shirish ^b   Khamashta, Munther A ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; VITAMIN D; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RETROSPECTIVE STUDY; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG SUBSTITUTION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; WARFARIN;

EID: 79961220976     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.150268     Document Type: Article

References (20)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Dentali F, Manfredi E, Crowther M, et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005;3:2121-3. (Pubitemid 43086081)
3. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994;170:862-9. (Pubitemid 24224715)
4. Ruiz-Irastorza G, Khamashta MA, Hughes GR. Heparin and osteoporosis during pregnancy:2002 update. Lupus 2002;11:680-2.
5. Watson HG, Keeling DM;BCSH Taskforce in Haemostasis and Thrombosis. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;135:269. (Pubitemid 44401628)
6. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-18. (Pubitemid 43867702)
7. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun 2009;33:92-8.
8. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-8. (Pubitemid 37122325)
9. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53. (Pubitemid 41632808)
10. Frank M, Sodin-Semrl S, Rozman B, et al. Effects of low-molecular-weight heparin on adhesion and vesiculation of phospholipid membranes: a possible mechanism for the treatment of hypercoagulability in antiphospholipid syndrome. Ann NY Acad Sci 2009;1173:874-86.
11. Lee AY, Levine MN, Baker RI, et al.;Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53. (Pubitemid 36818784)
12. Santoro R, Iannaccaro P, PrejanòS, et al. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. Blood Coagul Fibrinolysis 2009;20:240-3.
13. Bick RL, Rice J. Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety-a preliminary report. Clin Appl Thromb Hemost 1999;5(Suppl 1):S67-71. (Pubitemid 29529684)
14. Ahmed S, Karim A, Patel D, et al. Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome. Am J Med Sci 2002;324:279-80. (Pubitemid 35278774)
15. Wawrzynska L, Tomkowski WZ, Przedlacki J, et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003;33:64-7. (Pubitemid 37449280)
16. van der Heijden J F, Hutten BA, Büller HR, et al. Vitamin K antagonists or lowmolecular- weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002;1:CD002001.
17. Hull RD, Pineo GF, Brant RF, et al.; LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007;120:72-82.
18. Messmore H, Jeske W, Wehrmacher W, et al. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Saf 2003;26:625-41. (Pubitemid 36871836)
19. Breddin HK, Hach-Wunderle V, Nakov R, et al.; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety. Effects of a lowmolecular- weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001;344:626-31. (Pubitemid 32183577)
20. Hirsh J. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004;2:1003.